Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 12Gastrointestinal 7Gynecologic 4Thoracic 3Dermatologic 2CNS 2Breast 2Sarcoma 1Lymphoid 1Head & Neck 1Genitourinary 1

Conditions

Melanoma 15Parkinson Disease 4, Autosomal Dominant Lewy Body 5Neoplasm Metastasis 3Uveal Melanoma 2Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Transitional Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Brain Neoplasms 1

Interventions

pembrolizumab 40Nivolumab 18trametinib 13Cyclophosphamide 13dabrafenib 11Vemurafenib 10Interleukin-2 10Ipilimumab 9fludarabine 7Docetaxel 7fludarabine phosphate 6cemiplimab 6Paclitaxel 6Cisplatin 6Carboplatin 6atezolizumab 5Radiotherapy 5Drug Therapy 5Dacarbazine 5Blood Specimen Collection 5Biopsy 5poly ICLC 4binimetinib 4Therapeutics 4Psychiatric Rehabilitation 4sotigalimab 3montanide ISA 51 3encorafenib 3cobimetinib 3budigalimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × lenvatinib × Dermatologic × Clear all
NCT05620134 2024-10-15

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Salubris Biotherapeutics Inc

Phase 1/2 Active not recruiting
263 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT00121680 2015-12-11

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

Eisai Inc.

Phase 1 Completed
115 enrolled
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡